Whose share price almost tripled overnight?

Moderna is back in investor's good graces after announcing positive results from a Phase 3 trial of a cancer vaccine being conducted with MSD, the first positive Phase 3 readout for an individualised neoantigen therapy and for an mRNA-based cancer therapy.